NL-OMON36902已完成不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, THREE-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THE HP-3070 PATCH (ASENAPINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO SINGLE-DOSE SYCREST® 5 MG (ASENAPINE, SUBLINGUAL) IN HEALTHY ADULT MALE AND FEMALE SUBJECTS - HP -3070 Patch relative bioavailability study
oven Pharmaceuticals, Inc.0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Gezonde mannen en vrouwen
- •18-45 jaar
- •niet rokend
- •BMI 18-30 incl
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, FOUR-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF THE HP-5000 PATCH (DICLOFENAC SODIUM TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO FLECTOR® AND VOLTAREN® 100 MG IN HEALTHY ADULT MALE AND FEMALE SUBJECTS UNDER FASTING CONDITIONSontstekingeninflammationNL-OMON37576oven Pharmaceuticals, Inc.18
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 4-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF FLURBIPROFEN FOLLOWING ADMINISTRATION OF 2 FLURBIPROFEN TRANSDERMAL FORMULATIONS COMPARED TO FROBEN® 50 MG AND YAKUBAN TAPE® IN HEALTHY SUBJECTSontstekingenInflammationNL-OMON38802PRA International EDS18
已完成
不适用
A study to assess effect of ursolic acid extract in the body of healthy human volunteersCTRI/2013/04/003596Clinfound Clinical Research Services Pvt Ltd2
已完成
不适用
A prospective Clinical Study on a herbal Ursolic Acid extract in healthy volunteers to assess the pharmacokinetic effects.CTRI/2012/10/003044Clinfound Clinical Research Services P Ltd12
已完成
不适用
A SINGLE-CENTER, OPEN-LABEL, ONE-SEQUENCE, THREE-PERIOD CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF HP-3040 PATCHES (TOLTERODINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 168-HR APPLICATION COMPARED TO SINGLE-DOSE DETROL® LA 2 MG (TOLTERODINE TARTRATE EXTENDED RELEASE CAPSULE) IN HEALTHY ADULT MALE SUBJECTSurine incontinentieinvoluntary leakage of urineloss of bladder controlNL-OMON37479oven Pharmaceuticals, Inc12